newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

  • FDA accepted NDA for ulixacaltamide in Essential Tremor with a PDUFA date of January 29, 2027
  • FDA accepted NDA for relutrigine in SCN2A & SCN8A developmental epileptic encephalopathies (DEEs) with priority review & a PDUFA date of September 27, 2026
  • EMBRAVE Part A results showed elsunersen achieved a 77% placebo-adjusted reduction in monthly seizures for early-seizure onset SCN2A-DEE
  • POWER1 study topline results for vormatrigine in focal onset seizures are expected in Q2 2026
  • Relutrigine EMERALD study recruiting is complete with topline results anticipated in Q4 2026
  • Cash & investments totaled approximately $1.4 billion as of March 31, 2026, maintaining a runway into 2028
  • R&D expenses were $78.0 million for Q1 2026, up from $60.8 million in Q1 2025
  • G&A expenses were $27.9 million for Q1 2026, up from $13.9 million in Q1 2025
  • Net loss for Q1 2026 was $92.6 million compared to $69.3 million in Q1 2025
  • Praxis reported 27.9 million shares of common stock outstanding as of March 31, 2026